Table 1 Study characteristics
Reference | Study period, country | Study design, # of patients | 5-HT3 dose/day | Intervention, examination timing | Outcomes examined |
|---|---|---|---|---|---|
Hesketh [18] | NR, USA | Non-RCT, 44 | IV dolasetron 1.2 mg/kg, 1.8 mg/kg, 2.4 mg/kg 30 mins before chemotherapy | ECG, 1–2 hrs and 24–48 hrs | PR, QT |
Gralla [19] | August 2000 to October 2001, Germany, Italy, UK, Netherlands, Russia | RCT, 98 | IV palonosetron 0.25 mg, IV palonosetron 0.75 mg, IV ondansetron 32 mg 30 mins before chemotherapy | ECG, 15 mins, 24 hrs, 1 wk | Mortality, QT |
Kim [20] | April 2002 to October 2002, South Korea | RCT, 114 | IV dolasetron 100 mg 30 mins before and 200 mg p.o. 2-5 days after chemotherapy, IV ondansetron 8 mg 30 mins before and IV ondansetron 16 mg 2–4 hrs plus an additional 16 mg/day p.o. 2-5 days after chemotherapy | ECG, 15 mins, 24 hrs, 1 wk | ECG findings unspecified |